跳至主要内容
临床试验/NCT07835451
NCT07835451已完成不适用

Evaluation of the Effect of Bone Graft Materials on Peri-Implant Phenotype: A Prospective Three-Arm Controlled Interventional Clinical Study

Al-Mustansiriyah University1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2026年7月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
39
试验地点
1
主要终点
Ridge Width Changes (RW)

研究概览

简要总结

This prospective three-arm controlled interventional clinical study evaluates the effects of NanoBone alone and NanoBone combined with platelet-rich fibrin (PRF) on peri-implant hard and soft tissue phenotype after dental implant placement. Thirty-nine adult participants requiring dental implant therapy will be assigned to three groups of 13 using a repeating sequential 1-2-3 allocation sequence: implant placement alone (control), implant placement with NanoBone, or implant placement with NanoBone and PRF/CGF membrane. Clinical and radiographic outcomes will be assessed at baseline, immediately after surgery, 8 weeks after surgery, and 4 months after surgery, with an early postoperative assessment of pain, swelling, medication use, and wound healing.

详细描述

This is a prospective, three-arm, controlled interventional clinical study conducted at the Department of Periodontics, College of Dentistry, Mustansiriyah University, Baghdad, Iraq. The study evaluates the effects of NanoBone alone and NanoBone combined with platelet-rich fibrin (PRF) or a CGF/PRF membrane on peri-implant hard and soft tissue phenotype after dental implant placement.

The study includes 39 adults aged 18 to 70 years of either sex, with 13 participants assigned to each of three groups. Participants are recruited consecutively from patients seeking implant treatment at the postgraduate clinics of the Department of Periodontics. Allocation is performed using a pre-established repeating sequential 1-2-3 sequence. Because this sequence is predictable and is not true randomization, the study uses non-randomized sequential cyclic allocation.

Group 1 is the control group and receives dental implant placement without an adjunctive graft or platelet concentrate. Group 2 receives dental implant placement with 200 mg of NMImETIC Swelling NanoBone (Tavakol BioMimetic Technologies Co., Iran; granule size 500-1000 micrometers), moistened with sterile 0.9% sodium chloride and distributed around the implant site. Group 3 receives dental implant placement with NanoBone sticky bone and a CGF/PRF membrane. For this group, venous blood is collected immediately before surgery in tubes without anticoagulant. Autologous fibrin glue is mixed with 200 mg of NanoBone to form a cohesive sticky-bone material, and the remaining blood components are processed to produce a concentrated growth factor/platelet-rich fibrin membrane that covers the graft before wound closure. All groups receive the same preoperative preparation, implant-placement protocol, postoperative care, and follow-up routine except for the assigned adjunctive treatment.

Eligibility criteria include adults aged 18 to 70 years, ability to maintain oral hygiene and attend follow-up, healed edentulous ridges scheduled for delayed implant placement, adequate bone height and width for conventional implant placement, systemic health compatible with surgery and healing, and absence of infection or previous augmentation at the implant site. Exclusion criteria include uncontrolled systemic disease, pregnancy, active periodontal or periapical infection, severe ridge deficiency requiring complex reconstruction, metabolic bone disorders, bruxism or clenching, limited mouth opening, anatomical limitations preventing safe implant placement, inability or unwillingness to attend follow-up, and smoking, tobacco chewing, or alcohol consumption according to the study criteria.

Clinical and radiographic assessments are performed at baseline, immediately after surgery, 7 days after surgery, 8 weeks after surgery, and 4 months after surgery. Baseline assessments include plaque index, bleeding on probing, keratinized tissue width, soft tissue thickness at crestal/occlusal, buccal, and lingual or palatal sites, ridge width, and calculated bone width. Immediate postoperative assessments include ridge width and radiographic mesial bone height. The 7-day visit includes patient-reported pain, swelling, medication use, wound healing, adverse events, and suture removal when appropriate. The 8-week assessment includes plaque index, bleeding on probing, keratinized tissue width, and ridge width. The 4-month assessment includes plaque index, bleeding on probing, keratinized tissue width, soft tissue thickness, ridge width, calculated bone width, and radiographic mesial peri-implant bone height.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •• Adults aged 18 years or older, of either sex.
  • •Patients able to maintain an acceptable standard of oral hygiene and comply with study instructions.
  • •Healed edentulous ridges scheduled for delayed implant placement at least six months after tooth extraction.
  • •Straightforward implant sites with sufficient alveolar bone height and width for conventional implant placement.
  • •Systemically healthy patients without a medical condition expected to interfere with surgery, wound healing, or osseointegration.
  • •The implant location was required to be devoid of previous bone augmentation operations.
  • •Absence of behavioral or psychological conditions that could compromise treatment cooperation or follow-up attendance.
  • •Loss of one or more teeth requiring implant-supported rehabilitation.

排除标准

  • •• Uncontrolled systemic disease or any condition that could impair normal healing or prevent safe surgical treatment, including uncontrolled diabetes mellitus.
  • •Current pregnancy.
  • •Active periodontal, periapical, or other infection or inflammation at the planned implant site.
  • •Severe ridge deficiency requiring complex reconstruction rather than the standardized study procedure.
  • •Metabolic bone disorders, including severe osteoporosis or osteogenesis imperfecta.
  • •Parafunctional habits such as bruxism or clenching.
  • •Limited mouth opening that could restrict clinical measurements or surgical access.
  • •Anatomical limitations that prevented safe implant placement without additional modification, including close proximity to major nerves or the maxillary sinus.
  • •Inability or unwillingness to attend the scheduled follow-up visits.
  • •Individuals who adhere to social customs such as smoking, chewing tobacco, or consuming alcohol

研究组 & 干预措施

Control Group

Active Comparator

Participants receive dental implant placement without the addition of bone graft material or bone substitute.

干预措施: Dental implant placement (Procedure)

Group 2: Dental Implants + Nanobone

Experimental

Patients receive dental implants combined with Nanobone

干预措施: NanoBone (Other)

Group 3: Dental implant with Nanobone and PRF

Experimental

Patients receive standard dental implants placement with Nanobone and PRF

干预措施: NanoBone sticky bone plus CGF/PRF membrane (Other)

结局指标

主要结局

Ridge Width Changes (RW)

时间窗: Bassline, Immediately after surgery, 8 weeks after surgery, and 16 weeks after surgery

Bone Width (BW)

时间窗: Baseline (preoperative), and 16 weeks after surgery.

Change in width of keratinized tissue (KTW)

时间窗: Baseline (preoperative), 8 weeks after surgery and 16 weeks after surgery.

Keratinized Tissue Thickness (KTT)

时间窗: Baseline (preoperative) and 16 weeks after surgery.

Crestal Bone Height (BH)

时间窗: Immediate postoperative and 16 weeks after surgery.

次要结局

  • Plaque Index (PI)(Baseline (preoperative), 8 weeks after surgery and 16 weeks after surgery.)
  • Bleeding On Probing (BOP)Index .(Baseline (preoperative), 8 weeks after surgery and 16 weeks after surgery.)
  • Postoperative Pain ( Visual Analog Scale (VAS) )(Postoperative First week daily 3 Times (morning, afternoon, evening))
  • Postoperative Swelling Severity Using a Four-Point Likert Scale(Postoperative First week daily 3 Times (morning, afternoon, evening))

研究者

发起方
Al-Mustansiriyah University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ruqaiah Omar Haidar Ahmed

Principal Investigator

Al-Mustansiriyah University

研究点 (1)

Loading locations...

相似试验